Introduction
============

Chronic obstructive pulmonary disease is a major public health problem in many countries. The World Health Organization estimates that 210 million people have moderate to severe chronic obstructive pulmonary disease and that three million people died of the condition in 2005.[@ref1] Chronic obstructive pulmonary disease is associated with a substantial economic burden; estimates of cost include \$49.9 (£31.5; €36.3) billion in the United States in 2010 and \$1.5 billion in the United Kingdom in 2004.[@ref2] [@ref3] The course of the disease is characterised by episodes, known as acute exacerbations, when symptoms of cough, sputum production, and breathlessness become much worse. These are a frequent cause of admission to hospital, estimated to cost approximately \$73 billion a year in the United States and \$700 million a year in Australia and Canada.[@ref4] [@ref5] [@ref6] Standard prehospital management of an acute exacerbation of chronic obstructive pulmonary disease includes nebulised bronchodilators (usually driven by 6-8 l/min of oxygen), corticosteroids, and oxygen.

Oxygen is commonly administered to patients with an acute exacerbation of chronic obstructive pulmonary disease, as well as for a range of other medical emergencies,[@ref7] [@ref8] and can save lives by preventing severe hypoxaemia. Administration of high flow oxygen to normal people leads to an increase in the minute ventilation (the volume of air inspired into or expired out of the lungs in one minute) and a decrease in end tidal carbon dioxide concentration.[@ref9] [@ref10] However, even in patients with stable chronic obstructive pulmonary disease, hyperoxia leads to a decrease in minute ventilation and an increase in transcutaneous carbon dioxide.[@ref11] These changes are postulated to occur as a result of either depression of ventilation or worsening inequality in ventilation-perfusion due to recruitment of poorly ventilated lung units (alveolus and associated pulmonary capillaries where gas exchange takes place) by reversal of local hypoxic pulmonary vasoconstriction subsequently releasing sequestered carbon dioxide.[@ref8] Oxygen induced changes in carbon dioxide concentrations in chronic obstructive pulmonary disease were first shown in 1955,[@ref12] several years after a report on the deleterious effects of oxygen in this condition.[@ref13] Campbell was then fundamental in establishing the in-hospital practice of titrating oxygen treatment by using venturi masks.[@ref14] Subsequently, mortality in acute exacerbations of chronic obstructive pulmonary disease was reported to be associated with an increase in chronic stable levels of arterial carbon dioxide pressure, rather than the absolute level of hypercapnia.[@ref15]

More recently, audits of hospital management have shown that the administration of high flow oxygen during acute exacerbations of chronic obstructive pulmonary disease has been associated with increases in mortality, length of hospital stay, requirement for ventilation, and admission to high dependency units.[@ref16] [@ref17] [@ref18] [@ref19] [@ref20] Furthermore, the use of titrated oxygen treatment has been associated with less acidosis, a lower requirement for assisted ventilation, and reduced mortality.[@ref15] [@ref20] A one year prevalence study showed that the injudicious use of oxygen treatment caused acidosis in patients with acute exacerbations of chronic obstructive pulmonary disease, but a proportion of these patients were rapidly able to correct their pH once the fraction of inspired oxygen was reduced.[@ref19] Despite the accumulating evidence, high flow oxygen treatment continued to be the standard of care in Australia and other countries up to the time this trial started.[@ref7] [@ref17] [@ref21] [@ref20] In recent years, awareness of the potential harm of routine use of high flow oxygen has increased, and attempts have been made to modify practice. Concern about the routine use of high flow oxygen to relieve breathlessness in emergency settings has prompted the release of the first international guidelines for the emergency use of oxygen,[@ref8] but the need for randomised controlled trials is widely acknowledged.[@ref8] [@ref16] [@ref19] [@ref22] [@ref23] A recent Cochrane review on oxygen treatment and acute exacerbations of chronic obstructive pulmonary disease in the prehospital setting identified two ongoing trials, reinforcing the medical community's recognition of the need for evidence in this area.[@ref22] [@ref24] [@ref25]

Despite published guidelines, the lack of clear evidence showing the benefit of titrated oxygen treatment may be responsible for the lack of widespread cultural change among practitioners, authorities, and opinion leaders. The difficulty in modifying practice in the prehospital setting is compounded by the lack of equipment capable of delivering controlled oxygen treatment while administering nebulised drugs in ambulances. This study was motivated by the need for quantitative evidence on the dangers of high flow oxygen, to support recommendations for the use of titrated oxygen treatment for patients with an acute exacerbation of chronic obstructive pulmonary disease. Our ultimate objective is to improve the quality of care for patients. The aim of this study was to compare standard high flow oxygen treatment with titrated oxygen treatment for patients with an acute exacerbation of chronic obstructive pulmonary disease in the prehospital setting.

Methods
=======

Participants
------------

The study population comprised people aged 35 years or older with breathlessness and a history or risk of chronic obstructive pulmonary disease. Paramedics at the site of the emergency determined the diagnosis on the basis of appropriate acute symptoms, a history of chronic obstructive pulmonary disease (or emphysema) from the patient, or a greater than 10 pack year history of smoking. The study period was June 2006 to July 2007, and all participants were transported by ambulance and admitted to the Royal Hobart Hospital. This is located in the Tasmanian state capital of Hobart and is the major general hospital serving southern Tasmania (population approximately 250 000).

Randomisation
-------------

The study was a randomised, controlled, parallel group trial with two arms: paramedics in the active arm administered titrated oxygen treatment and those in the control arm administered conventional high flow oxygen treatment. We invited paramedics from the Tasmanian Ambulance Service to participate in the study and used cluster randomisation to assign them to one of the treatment groups. We used computerised random number generation after stratification by rurality, to reduce differences associated with transportation time between urban and rural areas. This procedure ensured that treatment allocation was concealed before randomisation. Neither paramedics nor the research team were blinded to treatment after randomisation. In situations in which multiple paramedics attended a patient and had been allocated to different study arms, the paramedic responsible for treatment was to deliver oxygen according to his or her treatment allocation. We informed nursing and medical staff at the emergency department of Royal Hobart Hospital about the trial and asked them to take an arterial blood gas sample from each patient immediately on arrival. We asked paramedics to inform hospital staff on arrival that a patient was enrolled in the study and to request the same ongoing oxygen treatment until an arterial blood gas sample had been taken. Hospital staff were thus not blinded to the treatment allocation. The ethics committee waived patients' consent, for pragmatic reasons in an acute emergency situation and because high flow oxygen treatment was the default standard practice in the Tasmanian Ambulance Service when the study started. To avoid contamination across treatment groups, we chose paramedics rather than patients as the unit of randomisation.

Interventions
-------------

Patients in the active arm received titrated oxygen treatment delivered by nasal prongs to achieve arterial oxygen saturations between 88% and 92%, with concurrent bronchodilator treatment administered by a nebuliser driven by compressed air (Walkie nebulisation air compressors, FlaemNova, Milan, Italy) and delivered via a facemask over the nasal prongs. The control arm received high flow oxygen treatment (8-10 l/min) administered by a non-rebreather face mask and bronchodilators delivered by nebulisation with oxygen at flows of 6-8 l/min. Pulse oximeters were used to measure oxygen saturations and titrate oxygen to target saturations in the active arm. Oximeters were also used to measure oxygen saturation in the high flow oxygen arm. The oximeters were built into the MRL (Welch Allyn, New York, USA) and MRX (Phillips Medical Systems, Andover, USA), had no alarm boundaries programmed, and had a visual readout only. Oxygen saturations were recorded on the ambulance report form.

All patients received other standard treatment according to Tasmanian Ambulance Service guidelines, including basic support, nebulised bronchodilators (salbutamol 5 mg made up in 2.5 ml normal saline, ipratropium bromide 500 μg made up with 2.5 ml normal saline), dexamethasone 8 mg intravenously, and, where necessary, salbutamol 200-300 mg intravenously or 500 mg intramuscularly.

Data collection
---------------

Patients entered into the study were identified by two means. Paramedics annotated ambulance report forms to indicate patients who were entered into the trial to facilitate subsequent identification of these patients by the research team. The emergency department at Royal Hobart Hospital also supplied a list of all patients transported by ambulance with a respiratory diagnosis, which the research team cross checked against ambulance records to compile a complete list of patients included in the study. We retrospectively defined a subgroup with chronic obstructive pulmonary disease as those patients with a definite diagnosis of chronic obstructive pulmonary disease, as defined by national guidelines.[@ref5] A respiratory physician blind to treatment allocation reviewed lung function data and smoking history, from private and public medical records. Only lung function data recorded in the five years before study entry were considered. Patients with no lung function data or who did not fulfil spirometric criteria for chronic obstructive pulmonary disease were excluded from the subgroup analyses. Royal Hobart Hospital provided data on arterial blood gas results taken within 30 minutes of arrival at the emergency department, requirement for invasive (endotracheal intubation) or non-invasive ventilation, the length of stay in hospital, and mortality. Length of treatment in the ambulance and oxygen saturation during prehospital management came from the Tasmanian Ambulance Service's records. Data were missing from both the ambulance and hospital patient records, so the denominators vary among analyses.

Statistical analysis
--------------------

We used the oxygen dissociation curve and Kelman's equation to determine whether blood gas samples were arterial or venous if this had not been recorded.[@ref26] We compared the measured arterial oxygen concentrations with the concentrations calculated from pulse oximetry at the time of the blood gas sample. We took a difference greater than 5% between the calculated and measured oxygen concentrations to indicate that the blood gas was a venous sample. For venous samples, we used the formulations described by Ak to estimate arterial values for pH, carbon dioxide, and bicarbonate.[@ref27] We used non-paired Student's *t* tests to compare arterial and converted venous blood gases. As no significant differences existed between arterial or converted venous samples for pH, carbon dioxide, or bicarbonate, we combined them for subsequent analyses. We could not convert venous oxygen concentrations, as comparative arterial oxygen concentrations are not provided in the conversion equations, and we thus report only measured arterial oxygen concentrations.

The primary outcome was prehospital and in-hospital mortality. We used log binomial regression to compare the risk of death for patients in the two treatment arms. We compared secondary outcomes---namely, length of hospital stay and blood gas measurements (pH, arterial carbon dioxide, bicarbonate, and arterial oxygen)---by using Student's *t* tests after transformation to remove skewness. We combined ventilation categories (invasive and non-invasive), as the number of observations was small, and used log binomial regression to compare them. We based initial analyses on the intention to treat principle and restricted a further set of per protocol analyses to patients who received treatment that complied with the study protocol. We did all analyses for all study patients and for the subgroup of patients with chronic obstructive pulmonary disease confirmed by lung function tests. We adjusted standard errors to account for any correlation between observations for the same paramedic (clustering). We used Intercooled Stata 10 for Windows for all analyses and considered a P value of 0.05 to be statistically significant.

For the primary outcome measure, mortality, we did power calculations assuming a 12% absolute difference in mortality between treatment arms, based on the study by Denniston et al.[@ref16] We calculated that a total of 200 participants (100 in each of two equal sized groups) would provide 83% power to detect a 70% reduction in mortality, from 14% in the high flow oxygen treatment arm to 2% in the titrated oxygen treatment arm. This sample size would also provide 94% power to detect a difference in arterial carbon dioxide pressure of 10 mm Hg (common SD 20 mm Hg) between the two groups. We allowed for a 25% dropout rate and thus needed a minimum of 135 participants in each arm.

Results
=======

We received consent to participate from 62 (98%) of the 63 full time paramedic staff, who had a one month familiarisation and training period before data collection started. Paramedics were equally distributed between the two treatment arms with regard to rurality, training, and experience (table 1[](#tbl1){ref-type="table"}). The paramedics transported 405 eligible patients to the Royal Hobart Hospital during the 13 month study period: 226 were treated by paramedics assigned to the high flow oxygen arm and 179 by those in the titrated oxygen arm. The subgroup of patients with chronic obstructive pulmonary disease confirmed by lung function tests contained 214 of the study patients: 117 were treated by paramedics assigned to the high flow oxygen arm and 97 by those in the titrated oxygen arm (figure[](#fig1){ref-type="fig"}). Seventy-nine (37%) randomised patients, 25 in the high flow arm and 54 in the titrated arm, did not receive treatment according to protocol, leaving 43 patients in the titrated oxygen arm and 92 patients in the high flow oxygen arm for the per protocol analyses.

###### 

 Baseline characteristics of treating paramedics. Values are numbers (percentages) unless stated otherwise

  Characteristic                  Control (high flow oxygen) (n=30)   Active (titrated oxygen) (n=32)
  ------------------------------- ----------------------------------- ---------------------------------
  Location:                                                           
   Urban                          23 (77)                             23 (72)
   Rural                          7 (23)                              9 (28)
  Qualification:                                                      
   Paramedic                      10 (33)                             8 (25)
   Intensive care paramedic       20 (67)                             24 (75)
  Mean (SD) years of experience   15.5 (8.3)                          16.7 (12.1)

![Flow of participants through study. COPD=chronic obstructive pulmonary disease; FEV~1~=forced expiratory volume in one second; FVC=forced vital capacity; ITT=intention to treat; TPP=treatment per protocol](ausm765461.f1_default){#fig1}

Baseline characteristics for all patients and for the subgroup of patients with confirmed chronic obstructive pulmonary disease did not differ significantly between the treatment arms in terms of age, sex, initial oxygen saturation, or prehospital treatment time (table 2[](#tbl2){ref-type="table"}). Patients in the chronic obstructive pulmonary disease subgroup did not differ significantly between groups in per cent predicted forced expiratory volume in one second or smoking history (table 2[](#tbl2){ref-type="table"}). Blood gas samples were taken after arrival at hospital in only 122 (57%) patients, and of these only 23 (19%) were arterial samples drawn within 30 minutes of arrival.

###### 

 Baseline characteristics for all patients and subgroup with confirmed diagnosis of chronic obstructive pulmonary disease (COPD). Values are mean (SD) unless stated otherwise

  Characteristic                            Control (high flow oxygen)   Active (titrated oxygen)
  ----------------------------------------- ---------------------------- --------------------------
  **All patients (n=405)**                                               
  No (%) male                               114/226 (50)                 83/179 (46)
  Age (years)                               69 (10.9) (n=202)            69 (11.8) (n=152)
  Prehospital treatment time (minutes)      47 (19) (n=156)              47 (18) (n=144)
  Pretreatment oxygen saturation (%)        86 (13.6) (n=189)            88 (9.8) (n=160)
  **Confirmed diagnosis of COPD (n=214)**                                
  No (%) male                               57/117 (49)                  45/97 (46)
  Age (years)                               68.0 (10.2) (n=117)          67.9 (10.3) (n=97)
  Per cent predicted FEV~1~                 42.1 (16.4) (n=117)          43.3 (16.5) (n=97)
  Smoking history (pack years)              45.5 (26.0) (n=87)           46.3 (22.1) (n=83)
  Prehospital treatment time (minutes)      47 (17) (n=87)               50 (19) (n=80)
  Pretreatment oxygen saturation (%)        84 (14) (n=101)              87 (10) (n=87)

FEV~1~=forced expiratory volume in one second.

In the intention to treat analysis for all patients, we found a significant difference between the two treatment arms for mortality (relative risk 0.42, 95% confidence interval 0.20 to 0.89; P=0.02) (table 3[](#tbl3){ref-type="table"}). Mortality was 9% (21 deaths) in the high flow oxygen arm compared with 4% (seven deaths) in the titrated oxygen arm. In the intention to treat analysis for the subgroup with confirmed chronic obstructive pulmonary disease, we also found a significant difference in mortality: 9% (11 deaths) in the high flow arm compared with 2% (two deaths) in the titrated oxygen arm (relative risk 0.22, 0.05 to 0.91; P=0.04) (table 3[](#tbl3){ref-type="table"}). All deaths occurred after arrival at hospital, including two in the emergency department and two in the intensive care unit. Respiratory failure was the primary cause of death in all cases, and approximately 70% of deaths occurred within the first five days of admission for both treatment arms.

###### 

 Intention to treat analysis. Values are numbers (percentages) unless stated otherwise

                                                                  Control (high flow oxygen)   Active (titrated oxygen)   Treatment effect        P value
  --------------------------------------------------------------- ---------------------------- -------------------------- ----------------------- ---------
  **Mortality**                                                                                                                                   
  All patients                                                    21/226 (9)                   7/179 (4)                  0.42 (0.20 to 0.89)\*   0.02
  Confirmed COPD                                                  11/117 (9)                   2/97 (2)                   0.22 (0.05 to 0.91)\*   0.04
  **Incidence of ventilation**                                                                                                                    
  All patients                                                    19/213 (9)                   13/166 (8)                 0.88 (0.45 to 1.72)\*   0.70
   Non-invasive ventilation                                       7                            8                                                  
   Invasive ventilation                                           12                           5                                                  
  Confirmed COPD                                                  15/105 (14)                  8/84 (10)                  0.67 (0.29 to 1.54)\*   0.34
   Non-invasive ventilation                                       6                            5                                                  
   Invasive ventilation                                           9                            3                                                  
  **Length of hospital stay (mean (SD) days)**                                                                                                    
  All patients                                                    5.9 (5.6) (n=226)            5.5 (5.9) (n=179)          −0.45 (0.57)†           0.19
  Confirmed COPD                                                  6.3 (5.8) (n=117)            5.4 (4.1) (n=97)           −0.88 (0.70)†           0.37
  **Arterial blood gases (\<30 min) (confirmed COPD patients)**                                                                                   
  Mean (SD) pH                                                    7.29 (0.14) (n=19)           7.35 (0.16) (n=19)         0.06 (0.05)†            0.11
  Mean (SD) carbon dioxide (mm Hg)                                77.8 (49.2) (n=20)           54.7 (31.1) (n=20)         −23.1 (13.0)†           0.06
  Mean (SD) bicarbonate (mmol/l)                                  32.3 (10.1) (n=19)           26.8 (6.5) (n=19)          −5.5 (2.76)†            0.07
  Mean (SD) oxygen (mm Hg) (arterial only)                        98.4 (46.1) (n=14)           79.3 (24.9) (n=9)          −19.1 (16.8)†           0.34

COPD=chronic obstructive pulmonary disease.

\*Relative risk (95% CI).

†Mean difference (SE).

In the intention to treat analysis for secondary outcomes, we found no significant differences between treatment arms for length of hospital stay or requirement for ventilation for all patients or the subgroup with confirmed chronic obstructive pulmonary disease (table 3[](#tbl3){ref-type="table"}). Arterial blood gas measurements did not differ significantly between groups, although only about 11% of patients had these done within 30 minutes of arrival at hospital. The mean time to blood gas analysis for all samples (venous and arterial) was 1 hour 41 minutes after arrival at hospital for the high flow oxygen group and 1 hour 46 minutes for the titrated group. Blood samples for gas analysis were drawn from 59/97 (61%) patients in the titrated oxygen arm and 63/117 (54%) in the high flow arm.

In the per protocol analysis for the subgroup with confirmed chronic obstructive pulmonary disease, we found significant differences between treatment arms for blood gas measurements (table 4[](#tbl4){ref-type="table"}). Patients who received titrated oxygen were significantly less likely to have respiratory acidosis (P=0.01) due to acute hypercapnia (P=0.02) than were patients who received high flow oxygen. We found no significant differences between treatment arms in length of hospital stay or requirement for ventilation for all patients or the subgroup with confirmed chronic obstructive pulmonary disease (table 4[](#tbl4){ref-type="table"}). Death rates were similar to those seen in the intention to treat analysis for all patients and the subgroup with confirmed chronic obstructive pulmonary disease, although the differences did not reach statistical significance (table 4[](#tbl4){ref-type="table"}).

###### 

 Treatment per protocol. Values are numbers (percentages) unless stated otherwise

                                                                  Control (high flow oxygen)   Active (titrated oxygen)   Treatment effect        P value
  --------------------------------------------------------------- ---------------------------- -------------------------- ----------------------- ---------
  **Mortality**                                                                                                                                   
  All patients                                                    16/177 (9)                   3/66 (5)                   0.50 (0.16 to 1.54)\*   0.23
  Confirmed COPD                                                  9/92 (10)                    1/43 (2)                   0.24 (0.04 to 1.57)\*   0.14
  **Incidence of ventilation**                                                                                                                    
  All patients                                                    19/167 (11)                  5/63 (8)                   0.70 (0.25 to 1.97)\*   0.50
   Non-invasive ventilation                                       7                            4                                                  
   Invasive ventilation                                           12                           1                                                  
  Confirmed COPD                                                  15/83 (18)                   3/40 (8)                   0.42 (0.14 to 1.20)\*   0.11
   Non-invasive ventilation                                       6                            2                                                  
   Invasive ventilation                                           9                            1                                                  
  **Length of hospital stay (mean (SD) days)**                                                                                                    
  All patients                                                    5.9 (5.5) (n=177)            6.0 (5.3) (n=66)           0.09 (0.78)†            0.87
  Confirmed COPD                                                  6.5 (6.0) (n=92)             6.2 (4.6) (n=43)           −0.29 (1.04)†           0.96
  **Arterial blood gases (\<30 min) (confirmed COPD patients)**                                                                                   
  Mean (SD) pH                                                    7.29 (0.15) (n=18)           7.41 (0.09) (n=10)         0.12 (0.05)†            0.01
  Mean (SD) carbon dioxide (mm Hg)                                76.5 (50.2) (n=19)           42.9 (14.2) (n=10)         −33.6 (16.3)†           0.02
  Mean (SD) bicarbonate (mmol/l)                                  31.5 (9.9) (n=18)            26.0 (4.2) (n=10)          −5.5 (3.30)†            0.15
  Mean (SD) oxygen (mm Hg) (arterial only)                        98.4 (46.1) (n=14)           81.5 (30.9) (n=6)          −16.9 (20.7)†           0.46

COPD=chronic obstructive pulmonary disease.

\*Relative risk (95% CI).

†Mean difference (SE).

Discussion
==========

We found that oxygen treatment, titrated by paramedics to achieve arterial oxygen saturations between 88% and 92%, for patients with breathlessness and a history or risk of chronic obstructive pulmonary disease, reduced the risk of death from respiratory failure by 58% for all patients and 78% for patients with confirmed chronic obstructive pulmonary disease, compared with high flow oxygen. For high flow oxygen treatment in patients with confirmed chronic obstructive pulmonary disease in the prehospital setting, the number needed to harm was 14; that is, for every 14 patients who are given high flow oxygen, one will die. Patients with chronic obstructive pulmonary disease who received titrated oxygen according to the protocol were also significantly less likely to have respiratory acidosis or hypercapnia.

Comparison with other studies
-----------------------------

This is the first randomised controlled trial of oxygen treatment for patients with a presumed acute exacerbation of chronic obstructive pulmonary disease in the prehospital setting. We used mortality as the primary outcome for the study because it is easily measured and is less subject to confounding than are other health outcomes such as length of stay in hospital. Our death rate of 9% in the high flow oxygen arm is similar to that seen in audits of patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease.[@ref28] [@ref29] Importantly, our study provides much needed support for recent recommendations that titrated oxygen, administered to achieve arterial oxygen saturations between 88% and 92%, should be used in emergency situations.[@ref8] [@ref19]

In the treatment per protocol analyses, patients with chronic obstructive pulmonary disease who received high flow oxygen were more likely to have respiratory acidosis with a significantly higher arterial carbon dioxide pressure. This is consistent with previous studies that have found that increased carbon dioxide and respiratory acidosis are associated with poor outcomes, including increased mortality.[@ref15] [@ref16] [@ref30] Reversal or prevention of these abnormalities by titrated oxygen has been associated with better in-hospital survival.[@ref19] [@ref31] [@ref32] Although patients given high flow oxygen were more acidotic, the arterial oxygen pressure did not differ greatly between groups, which may reflect the more rapid change that occurs in response to altering the fraction of inspired oxygen compared with pH and carbon dioxide.

We found that patients with an acute exacerbation of chronic obstructive pulmonary disease treated with titrated oxygen in the prehospital setting for an average time of 45 minutes were less likely to develop respiratory acidosis and die than were patients treated with high flow oxygen. Therefore, a dispersed population and lengthy treatment and transport times may maximise the potential adverse effects of high concentration oxygen treatment compared with areas and services that may have short treatment times. The population around Hobart is reasonably urbanised, but outlying rural areas give a rather mixed population, ideal for a generalisable study.

Strengths and limitations of study
----------------------------------

One limitation of our trial was the lower than expected rate of adherence to study protocols, in both prehospital oxygen treatment and the measurement of arterial blood gases on arrival at hospital, showing the difficulties associated with modifying practice. Of the 214 patients with confirmed chronic obstructive pulmonary disease, ambulance records showed that 37% received treatment that did not comply with the study protocol (56% in the titrated oxygen arm and 21% in the high flow oxygen arm). In the titrated oxygen arm, all protocol violations involved administration of high flow oxygen at some point during prehospital treatment. We expect that this would have minimised any treatment effect in the intention to treat analysis, but we still found a significant reduction in mortality for titrated oxygen treatment. The frequent lack of compliance in the titrated oxygen arm is probably a result of the entrenched culture and training in emergency medicine, which emphasises that high flow oxygen will save lives in acute respiratory emergencies by preventing severe hypoxaemia. From reviews of charts and interviews with paramedics, we found no evidence that the breaches of protocol were a result of malfunction of monitoring of saturation (oximeter), patients requesting more oxygen, or lack of understanding of the protocol. However, feedback indicated that some paramedics were concerned about insufficient delivery of oxygen in distressed patients, which suggests that they believed the entrenched cultural training that "more is better." This culture, combined with the absence of high quality evidence on the potential dangers of oxygen, may have been responsible for the ongoing practice of routine delivery of high flow oxygen.[@ref7] [@ref8] [@ref16] [@ref17] [@ref19] [@ref20] [@ref21] [@ref33] [@ref34] [@ref35]

A second limitation of this study was the low rate of arterial blood gas sampling for study patients. Although we informed staff in the emergency department staff of the importance of arterial samples for this trial, compliance was low and only 11% of arterial samples were drawn within 30 minutes of arrival. An audit of oxygen treatment in the prehospital setting by Wijesinghe et al also found a low rate of arterial blood gas sampling for patients with acute exacerbations of chronic obstructive pulmonary disease.[@ref20] The authors suggested several potential reasons for this, including refusal by patients, reluctance of the doctor to do the test, a perception by the doctor that the test is not indicated, or limited time and staff resources.[@ref20] In the emergency department at the time of the trial, the reasons given mainly related to limitations in staff time and resources but also to reluctance to do tests regarded as not clinically indicated. This supports again the difficulty in "real world" clinical trials of getting clinicians who are not investigators to engage with the ethos of the study, as well as the difficulty in using clinical trials to bring about change in management practices. The British Thoracic Society's guidelines on the management of acute exacerbation of chronic obstructive pulmonary disease recommend that all patients should have arterial blood gas sampling.[@ref8] The audit by Wijesinghe et al found that about a third of patients who had a blood gas measurement had respiratory failure, defined as an arterial carbon dioxide pressure of 45 mm Hg and a pH below 7.35, illustrating the importance of this recommendation.[@ref20] Ideally, for our study, a member of the research team would have been available to take arterial blood samples on arrival of the study patients, but unfortunately this was not practical.

In this study, we could not determine any effect of prehospital management on in-hospital management or differentiate the effects of prehospital and in-hospital oxygen management on measured outcomes. Review of the hospital records did not provide any further insight into the treatment after arrival in hospital. Titrated oxygen is the recommended treatment for breathless patients with a history or risk of chronic obstructive pulmonary disease at the Royal Hobart Hospital, but in practice, especially at the time of the trial, many of these patients received high flow oxygen on admission to hospital. However, any change in oxygen treatment that occurred after arrival in hospital would have reduced the differences between the treatment arms, thus underestimating the risk associated with high flow oxygen. Unfortunately, collection of data on in-hospital management was beyond the scope of the study, so we cannot dissect the effect of prehospital and in-hospital oxygen administration.

Conclusions and policy implications
-----------------------------------

This randomised controlled trial found that titrated oxygen treatment in the prehospital setting resulted in a 78% reduction in the risk of in-hospital respiratory failure and subsequent mortality, compared with high flow oxygen treatment, and a decreased risk of hypercapnia and respiratory acidosis for patients with an acute exacerbation of chronic obstructive pulmonary disease. Our findings provide the first high quality evidence from a randomised controlled trial for the development of universal guidelines and support the British Thoracic Society's recent guidelines on acute oxygen treatment, which recommend that oxygen should be administered only at concentrations sufficient to maintain adequate oxygen saturations. Although our findings may need to be confirmed in larger studies across other health systems, implementation of the new guidelines will now be easier. However, resources for an aggressive campaign of education will still be needed to change the "more is better" oxygen culture that may ignore the potential dangers of hyperoxia.

### What is already known on this topic

1.  Audits have shown increased mortality, acidosis, and hypercarbia in patients with acute exacerbations of chronic obstructive pulmonary disease treated with high flow oxygen

2.  High flow oxygen is still used routinely in prehospital and hospital areas for breathless patients with chronic obstructive pulmonary disease

3.  A "more is better" oxygen culture is strong in prehospital management

### What this study adds

1.  Titrated oxygen treatment reduces mortality, acidosis, and hypercarbia in patients with acute exacerbation of chronic obstructive pulmonary disease treated before arrival at hospital

2.  The risk of death was reduced by 78% by use of titrated oxygen rather than high flow oxygen, with a number needed to harm of 14

3.  These findings provide strong evidence that titrated oxygen treatment should be used for hypoxic or breathless patients with chronic obstructive pulmonary disease in prehospital settings
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